The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8228-8235

  Abou Ghazal, Mohamed ^a   Yng, David S ^a   Qiao, Wei ^a   Reina Ortiz, Chantal ^a   Wei, Jun ^a   Kong, Ling Yuan ^a   Fuller, Gregory N ^a   Hiraoka, Nobuyoshi ^b   Priebe, Waldemar ^a   Sawaya, Raymond ^a   Heimberger, Amy B ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN TISSUE; CANCER GRADING; CANCER INCIDENCE; CANCER INFILTRATION; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OLIGODENDROGLIOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; TISSUE MICROARRAY; BRAIN TUMOR; CHEMISTRY; GLIOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; GLIOMA; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 58149340584     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1329     Document Type: Article

References (65)

1. MasamuneA, Satoh M, Kikuta K, Suzuki N, Shimose-gawa T. Activation of JAK-STAT pathway is required for platelet-derived growth factor-induced proliferation of pancreatic stellate cells. World J Gastroenterol 2005;11:3385-91.
2. Huang S. Regulation of metastases by signal trans-ducerand activatorof transcription 3 signaling pathway: clinical implications. Clin Cancer Res 2007;13:1362-6.
3. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer2004;4:97-105.
4. Winston LA, Hunter T. JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. J Biol Chem 1995;270:30837-40.
5. Tarkowski E, Rosengren L, Blomstrand C, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995;26:1393-8.
6. Lau LT,Yu AC. Astrocytes produce and release inter-leukin-1, interleukin-6, tumor necrosis factor a and in-terferon-γ following traumatic and metabolic injury. J Neurotrauma 2001;18:351 -9.
7. DeSimoniMG,DelBoR,DeLuigiA,SimardS,For-loni G. Central endotoxin induces different patterns of interleukin (IL)-1 βand IL-6 messenger ribonucleic acid expression and IL-6 secretion in the brain and periphery. Endocrinology 1995;136:897-902.
8. McLoughlin RM, Jenkins BJ, Grail D, et al. IL-6 trans-signaling via STAT3 directsTcell infiltration in acutein-flammation. Proc Natl Acad Sci U S A 2005;102:9589-94.
9. Xie TX, Huang FJ, Aldape KD, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2006;66:3188-96.
10. Bao JJ, Fokt I, Szymanski S, Priebe W. Inhibition of constitutively active STAT3 by WP1066 suppresses proliferation and induces apoptosis in pancreatic can-cercells. Clin Cancer Res 2005;11:9026-7S.
11. Chakraborty A, Guha S, Helgason T, et al. A novel Jak2/STAT3 pathway inhibitor promotes apoptosis and blocks growth of bladder cancer cells. Los Angeles, (CA): 98th American Association of Cancer Research Annual Meeting; 2007.
12. Chan KS, Sano S, Kiguchi K, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004;114:720-8.
13. Guha S, Chakraborty A, Szymanski S, et al. WP1066, a potent inhibitorofJak2/STAT3 pathway inhibits pancreatic tumor growth both in vitro and in vivo. Los Angeles (CA): 98th American Association of Cancer Research Annual Meeting; 2007.
14. Iwamaru A, Szymanski S, Iwado E, et al. A novel inhibitorof the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2006;26:2435-44.
15. Kong L-Y, Kapuria V, Bartholomeusz G, Priebe W, Talpaz M, Donato N. Antitumoractivity and mechanism of action of a novel Stat3 inhibitor, WP1066, against human B-cell non-Hodgkin's lymphoma and multiple myeloma. Blood 2005;106:1489.
16. Kupferman ME, Zhou G, Zhao M, et al. A novel inhibitorof STAT3 signaling in head and neck squamous cell carcinoma. Washington (DC): 97th American Association of Cancer Research Annual Meeting; 2006.
17. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A 2003;100:4138-43.
18. Samanta A, Kantarjian H, Priebe W, Arlinghaus R. Cross talk between Jak2 and Lyn in Bcr-Abl signaling pathway in cells from Imatinib-sensitive and resistant chronic myelogenous leukemia (CML). Los Angeles (CA): 98th American Association of Cancer Research Annual Meeting; 2007.
19. Tang GS, Cai JM, Ni J, et al. Effects of STAT3 anti-sense oligodeoxynucleotides on apoptosis and proliferation of mouse melanoma cell line B16. Ai Zheng 2006;25:269-74.
20. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005;24:970-9.
21. Lang R, Patel D,Morris J, RutschmanR, Murray P. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 2002;169:2253-63.
22. O'Farrell AM, Liu YW, Moore KW, Mui AL. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence forStat3-de-pendent and -independent pathways. EMBO J 1998; 17:1006-18.
23. Takeda K, Clausen B, KaishoT, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999;10:39-49.
24. LinT, Bost K. STAT3 activation in macrophages following infection with Salmonella. Biochem Biophys Res Commun 2004;321:828-34.
25. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41 -51.
26. Kortylewski M,Yu H. Stat3 as a potential target for cancer immunotherapy. J Immunother (1997) 2007; 30:131-9.
27. Kortylewski M, Kujawski M,WangT, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11:1314-21.
28. Zorn E, Nelson EA, Mohseni M, et al IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006;108:1571 -9.
29. Hussain SF, Kong L-Y, Jordan J, et al. A novel small molecule inhibitorof signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007;67:9630-6.
30. Kong LY, Abou-Ghazal MK, Wei J, et al. A novel in-hibitorof STAT3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 2008;14:5759-68.
31. Heimberger AB, Reina-Ortiz C, Yang DS, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008; 5166-72.
32. Barnett JA, Urbauer DL, Murray GI, Fuller GN, Heimberger AB. CYP1B1 Expression in Glial Cell Tumors: An Immunotherapeutic Target. Clin Cancer Res 2007;13:3559-67.
33. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12:5423-34.
34. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames: Iowa State University Press; 1980.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
36. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
37. Heimberger AB,Hlatky R,SukiD,etal. Prognostic effect of epidermal growth factor receptor and EGFR-vIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11:1462-6.
38. Heimberger AB, McGary E, Suki D, et al. Loss of the AP-2α transcription factor is associated with the grade of human gliomas. Clin Cancer Res 2005;11:267-72.
39. Gong W, Wang L,Yao J, et al. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 2005;11:1386-93.
40. Horiguchi A, Oya M, ShimadaT, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of indicence and its association with pathological features and clinical outcome. J Urol 2002;168:762-5.
41. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al. Molecularand prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005;24:1053-65.
42. Masuda M, Suzui M,Yasumatu R. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002;62:3351 -5.
43. Shah NG,Trivedi TI,Tankshali RA. STAT3 expression in oral squamous cell carcinoma: association with clinicopathological parameters and survival. Int J Biol Markers 2006;21:175-83.
44. Yang S, Wang S, Wu C, et al. Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepa-tocellular carcinoma. J Clin Pathol 2007;60:642-8.
45. Khoury JD, Medeiros LJ, Rassidakis G, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 2003;9:3692-9.
46. Schlette E, Medeiros LJ, Goy A, Lai R, Rassidakis G. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004;22:1682-8.
47. Lassmann S, SchusterI, Walch A, et al. STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol 2007;60:173-9.
48. KusabaT, NakayamaT,Yamazumi K, et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 2005;58:833-8.
49. CortasT, Eisenberg R, Fu P, Kern J, Patrick L, Dowlati A. Activation state EGFR and STAT-3 as prognostic markers in resected non-small lung cancer. Lung Cancer 2007;55:349-55.
50. Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005;11:8288-94.
51. Yang S, Yuan S, Yeh Y, et al. The role of p-STAT3 (ser727) revealed by its association with Ki-67 in cervical intraepithelial neoplasia. Gynecol Oncol 2005;98:446-52.
52. Wang H,Wang H, ZhangW, Huang H, LiaoW, Fuller GN. Analysis of the activation status of Akt, NFkB, and STAT3 in human diffuse gliomas. Lab Invest 2004;84:941 -51.
53. Mizoguchi M, Betensky RA, BatchelorTT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuro-pathol Exp Neurol 2006;65:1181 -8.
54. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-oncol 2006;8:261 -79.
55. Brooks WH, Markesbery WR, Gupta GD, Roszman TL. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 1978;4:219-24.
56. von HanwehrRI, Hofman FM,TaylorCR, Apuzzo ML. Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies. J Neurosurg 1984;60:1138-47.
57. Strik HM, Stoll M, Meyermann R. Immune cell infiltration of intrinsic and metastatic intracranial tumours. Anticancer Res 2004;24:37-42.
58. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
59. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/reg-ulatoryTcell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-43.
60. Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007;13:902-11.
61. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-93.
62. Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-4+CD25 + T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13:2075-81.
63. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006;12:3355-60.
64. Blaskovich MA, Sun J, CantorA, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63:1270-9.
65. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of STAT3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 2007;104:7391-6.